Canaccord Genuity Group Has Lowered Expectations for TriSalus Life Sciences (NASDAQ:TLSI) Stock Price

TriSalus Life Sciences (NASDAQ:TLSI) had its price target lowered by research analysts at Canaccord Genuity Group from $12.00 to $7.00 in a research note issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective indicates a potential upside of 56.60% from the stock’s current price.

Other equities research analysts have also recently issued reports about the company. Wall Street Zen cut TriSalus Life Sciences from a “hold” rating to a “sell” rating in a research note on Sunday, February 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Monday, December 29th. Finally, Zacks Research upgraded TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 16th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $7.00.

TriSalus Life Sciences Trading Down 6.3%

Shares of TLSI stock opened at $4.47 on Friday. TriSalus Life Sciences has a 1 year low of $3.42 and a 1 year high of $7.95. The firm’s 50 day moving average is $5.36 and its 200-day moving average is $5.36. The firm has a market capitalization of $223.77 million, a price-to-earnings ratio of -2.44 and a beta of 0.42.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. The company had revenue of $13.21 million during the quarter, compared to analyst estimates of $13.20 million. On average, equities research analysts forecast that TriSalus Life Sciences will post -1.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Nantahala Capital Management LLC bought a new stake in TriSalus Life Sciences in the second quarter valued at about $10,900,000. AWM Investment Company Inc. acquired a new position in shares of TriSalus Life Sciences during the 2nd quarter worth about $6,812,000. Vanguard Group Inc. increased its stake in shares of TriSalus Life Sciences by 42.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock valued at $5,392,000 after acquiring an additional 345,186 shares during the last quarter. Gilder Gagnon Howe & Co. LLC increased its stake in shares of TriSalus Life Sciences by 32.1% in the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock valued at $5,957,000 after acquiring an additional 265,618 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in TriSalus Life Sciences by 107.4% during the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock worth $2,480,000 after acquiring an additional 235,627 shares during the last quarter. 2.58% of the stock is currently owned by institutional investors.

Trending Headlines about TriSalus Life Sciences

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: Q4 results slightly beat expectations — TLSI reported ($0.12) EPS vs. a ($0.13) consensus and revenue of $13.21M vs. $13.20M expected, a small but constructive beat that supports near‑term operational momentum. Earnings Call Highlights
• Positive Sentiment: Company reaffirmed FY2026 revenue guidance of $60M–$62M and said it is expanding its PEDD portfolio — guidance above Street revenue consensus may support longer‑term growth expectations. Guidance & PEDD Expansion
• Positive Sentiment: Brokerage support remains: Lake Street reaffirmed its buy stance, keeping institutional endorsement visible to investors. Lake Street Rating
• Neutral Sentiment: Full earnings call transcripts and coverage are available (useful for detail but not new headline items) — investors can review management commentary on growth initiatives and margins. Earnings Call Transcript
• Neutral Sentiment: Independent estimates and models updated by firms such as Northland provide refreshed forecasts but contain no single consensus surprise; these are reference points for investors modeling FY2026. Northland Estimates
• Negative Sentiment: Canaccord cut its price target from $12 to $7 while keeping a buy rating — the sizable downgrade in upside reduces some analyst‑driven upside expectations and likely pressured the stock despite the buy rating. Canaccord Price Target Cut

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.